William Napier, NP
Adult Health · Louisville, KYNPI 1730443763
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations.
Across 113 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$504
- Novo Nordisk$289
- AstraZeneca$223
- Lilly USA, LLC$163
- Amgen$146
- Pfizer$112
- plus $771 from 19 others
What the payments were for
- Food & beverage$2,208100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $504 |
| Novo Nordisk | 16 | $289 |
| AstraZeneca(2 entities) | 5 | $223 |
| Lilly USA, LLC | 5 | $163 |
| Amgen | 9 | $146 |
| Pfizer | 7 | $112 |
| Exact Sciences | 7 | $108 |
| GSK | 5 | $75 |
| Shield Therapeutics Inc | 2 | $70 |
| Boehringer Ingelheim | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Abbott | 3 | $49 |
| Astellas Pharma US Inc | 3 | $49 |
| Bayer | 3 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Dexcom, Inc. | 2 | $28 |
| Merck | 1 | $27 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$120
How this compares
$2,208 in reported general payments places this provider in the 80th percentile of 170 adult health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $58,758 |
| JardianceEmpagliflozin | 36 | $44,219 |
| OzempicSemaglutide | 29 | $42,422 |
| EliquisApixaban | 38 | $40,738 |
| MounjaroTirzepatide | 31 | $28,812 |
| JanuviaSitagliptin Phosphate | 26 | $28,070 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $27,089 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $23,690 |
| TradjentaLinagliptin | 11 | $8,563 |
| Potassium Chloride | 90 | $7,783 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $4,694 |
| Atorvastatin Calcium | 596 | $4,114 |
| Celecoxib | 88 | $3,339 |
| Wixela InhubFluticasone Propion/Salmeterol | 29 | $3,237 |
| Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl | 11 | $3,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $56 | $52,78247 claims |
| MerckJanuvia, Janumet Xr | $27 | $51,76044 claims |
| Novo NordiskOzempic, Levemir | $289 | $44,36441 claims |
| PfizerEliquis | $112 | $40,73838 claims |
| Lilly USA, LLCMounjaro | $163 | $28,81231 claims |
| GSKTrelegy Ellipta | $75 | $27,08945 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $1,510176 claims |
| AbbVieSynthroid | $504 | $1,47930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 adult health providers in Kentucky.
Other adult health in Louisville
- Stephanie FlaspoehlerLouisville$174K
- Heidi GalloLouisville$15K
- Karen EastridgeLouisville$10K
- Barbara CarpenterLouisville$8K
- Loren GarzaLouisville$6K
- Kelly MikeLouisville$4K
- Layla Al-ShamiLouisville$3K
- Brittany McWhorterLouisville$3K
- Lahoma PratherLouisville$2K
- Barbara LemmonsLouisville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.